Posted on June 19, 2020 by Sitemaster
Slowly but surely we are learning more about the roles of family history and familial genetics (heredity) in determining risk for prostate cancer — and most especially risk for clinically significant forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: family, germline, heredity, history, mutation, risk | 3 Comments »
Posted on June 11, 2020 by Sitemaster
The recommendations of the Philadelphia Prostate Cancer Consensus Conference 2019 (held in October last year) on implementation of germline testing for risk of prostate cancer have now been published in the Journal of Clinical Oncology. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: consensus, germline, risk, somatic, testing | 1 Comment »
Posted on April 17, 2019 by Sitemaster
In this week’s Journal of Clinical Oncology, there is a full-text article in the “Comments and Controversies” section entitled … READ MORE …
Filed under: Uncategorized | Tagged: DNA, genetic, genomic, germline, test | 2 Comments »
Posted on January 10, 2019 by Sitemaster
A newly published paper in the Journal of Clinical Oncology has confirmed — based on a prospective study (as opposed to retrospective data) — that there is a strong risk association between a germline mutation of the BRCA2 gene and risk for metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: BRCA2, germline, mutation, screening | 1 Comment »
Posted on October 25, 2018 by Sitemaster
Many people are increasingly interested in whether genetic testing can help them to understand their risk for cancer. The basic answer is that “Yes, it can.” However, what is also clear is that it is only going to be helpful for a small percentage of the population. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: genetic, genomic, germline, risk, test | 1 Comment »
Posted on October 17, 2017 by Sitemaster
Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: 3βHSD1, ADT, genetic, germline, HSD3B1, profile, response, Treatment | Leave a comment »
Posted on August 4, 2016 by Sitemaster
A new study in this week’s New England Journal of Medicine reports that DNA-repair germline mutations were found in nearly 12 percent of patients who had metastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: DNA, gene, germline, metastatic, mutation, repair, risk | 6 Comments »
Posted on July 7, 2016 by Sitemaster
A new study reported today in the New England Journal of Medicine is suggesting that every man with metastatic prostate cancer (regardless of his age or family history) should be tested for certain particular inherited mutations. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: advanced, castration-resistant, genetics, germline, metastatic, mutations | 2 Comments »